Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan
暂无分享,去创建一个
Kazuhiro Yoshida | Y. Maehara | K. Hirata | Y. Nakanishi | H. Baba | N. Yamamoto | M. Kitajima | T. Kamura | K. Tamura | M. Shimokawa | T. Saeki | Y. Kitagawa | K. Aiba
[1] R. Chow,et al. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis , 2016, Supportive Care in Cancer.
[2] Y. Hirashima,et al. Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy , 2015, BioMed research international.
[3] Kazuhiro Yoshida,et al. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan , 2015, International Journal of Clinical Oncology.
[4] E. Sato,et al. Safety and pharmacokinetic evaluation of repeated intravenous administration of palonosetron 0.75 mg in patients receiving highly or moderately emetogenic chemotherapy , 2014, Supportive Care in Cancer.
[5] R. Navari,et al. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy , 2013, Supportive Care in Cancer.
[6] M. Kris,et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] T. Perrone,et al. Palonosetron (Aloxi®) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy , 2009, Supportive Care in Cancer.
[8] G. de Pouvourville,et al. Incidence of chemotherapy‐induced nausea and emesis after modern antiemetics , 2004, Cancer.
[9] M. Stockler,et al. Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer , 2004, Supportive Care in Cancer.
[10] David Khayat,et al. Changing patient perceptions of the side effects of cancer chemotherapy , 2002, Cancer.
[11] J. Verweij,et al. Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy , 2001, British Journal of Cancer.
[12] S B Kaye,et al. On the receiving end--patient perception of the side-effects of cancer chemotherapy. , 1983, European journal of cancer & clinical oncology.
[13] M. Kris,et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.